Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP137 in advanced solid tumors
NCT02977195Phase 1Completed
- Sponsor
- Centre Léon Bérard
- Start
- Jan 2017
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, IgG Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of np137 in solid tumor and endometrial carcinoma, sponsored by Centre Léon Bérard. Primary endpoints: Dose-Limiting Toxicity at 4 weeks and Objective Response Rate at 3 months. Started Jan 2017; status: completed.
02
Drugs
np137
03
Conditions
solid tumorendometrial carcinoma
Beyond the preview
Go deeper on NCT02977195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977195.